切换导航
About Us
Our Story
Our Mission
History
Global Footprint
Leadership
Board of Directors
Science & Technology
Pipeline
Collaborations
CDMO Services
About CDMO
Strength
Services Offered
Learn More
Investors & Media
Join Us
EN
中文
Our RNA Encodes
Innovation
/science.html
Transforming Somatic Cells into a Drug Factory
View More
Latest news
News Update
Immorna’s mRNA Quadrivalent Seasonal Influenza Vaccine Obtains US. FDA IND Clearance
View More
2023.07.28
News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
View More
2023.05.31
News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
View More
2023.01.09
News Update
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
View More
2022.11.19
View All
Diverse pipeline utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA.
View More